FDA Embraces AI For Drug Reviews—A Bold Move Towards Rapid Approvals in the U.S.
Source: Fierce Biotech
The FDA is implementing an AI tool named Elsa to expedite drug application reviews, aiming to process initial submissions, sometimes exceeding 500,000 pages and analyzing it in a matter of minutes. Challenges remain as Elsa sometimes produces inaccurate or unreliable responses so all AI-generated outputs will still require human oversight.
Popular Blood Tests for Cancer—Oncologists Seek Stronger Evidence for ctDNA Tests
Source: StatNews
Oncologists recognize the growing interest of liquid biopsy tests that detect circulating tumor DNA (ctDNA), noting their potential to detect cancer activity earlier than traditional imaging like MRI or CT scans. However, they emphasize the need for stronger clinical evidence and standardized guidelines before these tests can be integrated into cancer care.
U.S. Import Regulations are Changing—Imported Prescription Drugs Must Now Comply with New Rules
Source: Euro-American Worldwide Logistics
Pharmaceutical and biotech companies importing into the U.S. face significant regulatory changes in 2025, including stricter Drug Supply Chain Security Act (DSCSA) serialization requirements, new country-of-origin labeling mandates that extend to pharmacy-dispensed medications, and enhanced enforcement of forced labor compliance.
